Format

Send to

Choose Destination
See comment in PubMed Commons below
Science. 2003 Sep 26;301(5641):1895-8.

Inactivation of TNF signaling by rationally designed dominant-negative TNF variants.

Author information

1
Xencor, 111 West Lemon Avenue, Monrovia, CA 91016, USA.

Abstract

Tumor necrosis factor (TNF) is a key regulator of inflammatory responses and has been implicated in many pathological conditions. We used structure-based design to engineer variant TNF proteins that rapidly form heterotrimers with native TNF to give complexes that neither bind to nor stimulate signaling through TNF receptors. Thus, TNF is inactivated by sequestration. Dominant-negative TNFs represent a possible approach to anti-inflammatory biotherapeutics, and experiments in animal models show that the strategy can attenuate TNF-mediated pathology. Similar rational design could be used to engineer inhibitors of additional TNF superfamily cytokines as well as other multimeric ligands.

PMID:
14512626
DOI:
10.1126/science.1081297
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center